Navigation Links
Lexicon Announces Commencement of Rights Offering to Stockholders
Date:11/22/2011

to initiate a pro rata rights offering to its stockholders.  Invus, L.P. and Invus C.V. will be required to exercise their basic subscription privileges in full and purchase at least 68,868,892 shares of common stock in the rights offering, subject to certain customary closing conditions, including the expiration or termination of any applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.  In light of the potential for the ownership percentage of Invus, L.P., Invus C.V. and their affiliates to increase to greater than 50% of Lexicon's outstanding common stock as a result of the rights offering, the parties have made the required filings for that purpose with the Premerger Notification Office of the Federal Trade Commission and the Antitrust Division of the Department of Justice.

Any questions from stockholders or requests for additional copies of the prospectus supplement and accompanying prospectus or other rights offering materials may be directed to BNY Mellon Shareowner Services, the information agent for the rights offering, at (800) 777-3674 from within the United States, Canada or Puerto Rico, or at (201) 680-6579 from outside the United States.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale is not permitted.  The offering of securities in the rights offering will be made only by means of the prospectus supplement and accompanying prospectus, copies of which may be obtained from BNY Mellon Shareowner Services as indicated above.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rhe
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Present LX4211 Clinical and Preclinical Data at Diabetes Conference
2. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
3. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
4. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
5. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
6. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
7. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
8. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
9. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
10. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
11. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... NEW YORK, May 6, 2015 Delcath Systems, ... medical device company focused on oncology with an emphasis ... announces financial results for the three months ended March ... quarter and recent weeks include: , Achieved quarterly ... than 43% compared with the first quarter of 2014; ...
(Date:5/6/2015)... , May 6, 2015 CVS Health (NYSE: CVS ... Baltimore locations that sustained heavy fire damage during ... in Baltimore over the past week or ... is ahead," said CVS Health President and CEO Larry Merlo ... path to better health. There is no better way that we ...
(Date:5/6/2015)... Fibich, Leebron, Copeland, Briggs & Josephson is ... been reached to resolve lawsuits involving individuals who were ... - manufactured by Takeda Pharmaceuticals - has been associated ... of the firm,s attorneys were instrumental in the coordination ... Fibich - Founding Partner of Fibich, Leebron, Copeland, ...
Breaking Medicine Technology:Delcath Reports 2015 First Quarter Financial Results 2Delcath Reports 2015 First Quarter Financial Results 3Delcath Reports 2015 First Quarter Financial Results 4Delcath Reports 2015 First Quarter Financial Results 5Delcath Reports 2015 First Quarter Financial Results 6Delcath Reports 2015 First Quarter Financial Results 7Delcath Reports 2015 First Quarter Financial Results 8CVS Health Announces it Will Rebuild Baltimore CVS/pharmacy Locations 2Takeda Agrees to $2.4 Billion Settlement for Actos Bladder Cancer Lawsuits 2
... JERSEY CITY, N.J., May 2, 2011 Aoxing ... Pharma"), a specialty pharmaceutical company focusing on research, ... products, announced that its operating subsidiary in China, ... a patent by the State Intellectual Property Office ...
... International, Inc. (NYSE: VRX ) (TSX: VRX) today ... and Cephalon, Inc. (NASADQ: CEPH) on their announcement that Cephalon ... the news, Valeant has withdrawn its consent solicitation. ... Cephalon stockholders and we are pleased that Teva has paid ...
Cached Medicine Technology:Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film 2Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film 3Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction 2
(Date:5/6/2015)... 06, 2015 As Hilo Medical ... EMR Adoption Model, the hospital looked for new ... and automate processes. The leadership team realized that ... electronic workflows, patient registration still required patients to ... With HIMSS Stage 7 attestation fast approaching, Hilo ...
(Date:5/6/2015)... Experienced Vancouver air conditioning installation and repair ... will now conduct their cooling services, including air conditioning ... commercial and residential units. Strata complex air conditioning services ... technical knowledge as well as a professionally trained staff. ... take away any old air conditioning unit to be ...
(Date:5/6/2015)... Vancouver, BC (PRWEB) May 06, 2015 ... colon hydrotherapy supplier, is excited to announce a ... will help reduce the industry’s carbon footprint while ... These kits feature Eco-Flex™, the world’s ... “This is a game-changer for hydrotherapists,” claims the ...
(Date:5/6/2015)... Animals make just as good friends as they do ... health. An Ohio veterinarian has been observing this ... health advantages of owning a pet. , “When animals and ... ownership, there are proven health benefits for people-- including physical, ... the Animal Medical Center of Streetsboro said. Every ...
(Date:5/6/2015)... Inversion Studios, a full-service training ... Pilates classes, provides personalized individual instruction and now ... its new Pilates Ring magic circle. , Inversion ... stronger, more centered and graceful, Inversion Studios and ... to healthy fitness through yoga and Pilates. With ...
Breaking Medicine News(10 mins):Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 2Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 3Health News:Pro Ace Care Now Does Air Conditioning Installation for Strata Complexes 2Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 2Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 3Health News:Veterinarian Supports 2015 HABRI Study Citing Increase in Health Advantages of Pet Owners 2Health News:Veterinarian Supports 2015 HABRI Study Citing Increase in Health Advantages of Pet Owners 3Health News:Inversion Studios’ New Pilates Ring Is Circle of Magic for Body, Mind and Spirit 2Health News:Inversion Studios’ New Pilates Ring Is Circle of Magic for Body, Mind and Spirit 3
... than that, after a lumpectomy for breast cancer. Researchers from ... ubiquitous tummy fat , can in fact be used to ... two birds with one stone, a flatter belly and a ... a 'supercharged' fat mixture into the breast tissue after it ...
... a genetic marker that increases a person's risk of colon ... 10-year study was conducted by a team of researchers from ... Public Health, the Catalan Institute of Oncology in Spain, the ... Israel Institute of Technology, including Stephen Gruber and Gad Rennert. ...
... announced today that ALIGN(R) is now available through ... builds and maintains a natural defense against ... as constipation, diarrhea, abdominal discomfort, urgency, gas and ... contains Bifantis(R) (Bifidobacterium infantis 35624), a natural probiotic ...
... western media, the government of the Peoples Republic of China ... the countrys Food and Drug Administration. ,,He was ... of dereliction of duty at a trial in May. ... led to several deaths. , ,China has been ...
... Microsoft, aware that a large number of Internet searches ... presence in the healthcare sector . This, claims Cambridge ... healthcare professionals and medical device manufacturers. According to a ... are already having to come to terms with informed ...
... to detect a disease in its very early ... slowly gaining greater acceptance across Europe . Furthermore, ... and invasive procedures, in addition to reducing bed ... Europe, age-related diseases such as cancer, Alzheimer's disease, ...
Cached Medicine News:Health News:Stem Cells In Belly Fat To Enhance Or Reconstruct Breasts 2Health News:Food Safety Chief Executed for Bribery in China 2Health News:Food Safety Chief Executed for Bribery in China 3Health News:Food Safety Chief Executed for Bribery in China 4Health News:Battle Between Google and Microsoft Could Trigger Revolution in Healthcare 2Health News:Pharmacogenomic Market Gaining Greater Acceptance Across Europe 2Health News:Pharmacogenomic Market Gaining Greater Acceptance Across Europe 3
QC 900 is an assayed quality control material for analyzers measuring hematocrit by electrical conductivity methodologies. It is available in two (2) levels for monitoring analyzer performance at var...
... 823 is an assayed quality ... the performance of blood gas, ... instrumentation. It is available in ... analyzer performance at varying points ...
... QC 463 is a quality control ... monitoring the performance of blood gas, electrolyte, ... practical alternative to the use of human ... in three (3) levels for monitoring analyzer ...
... and probe system used together to quantify ... based system is a sandwich nucleic acid ... for RNA detection and quantification, by amplifying ... technology. Branched DNA allows immediate quantification of ...
Medicine Products: